Bridgewater Associates LP purchased a new position in Solventum Co. (NYSE:SOLV - Free Report) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 18,875 shares of the company's stock, valued at approximately $1,316,000.
Other hedge funds also recently made changes to their positions in the company. Deseret Mutual Benefit Administrators acquired a new position in shares of Solventum during the 2nd quarter valued at $25,000. Hollencrest Capital Management bought a new stake in shares of Solventum during the 2nd quarter worth $25,000. Richard W. Paul & Associates LLC bought a new stake in Solventum during the 2nd quarter valued at approximately $26,000. Family Firm Inc. acquired a new stake in Solventum in the 2nd quarter worth $26,000. Finally, Copeland Capital Management LLC acquired a new stake in shares of Solventum during the 3rd quarter worth approximately $26,000.
Solventum Price Performance
NYSE:SOLV traded up $0.48 during trading hours on Monday, hitting $71.99. The company's stock had a trading volume of 984,365 shares, compared to its average volume of 1,685,013. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15. The stock has a fifty day simple moving average of $70.55 and a 200-day simple moving average of $62.58. Solventum Co. has a twelve month low of $47.16 and a twelve month high of $96.05.
Wall Street Analyst Weigh In
A number of equities research analysts recently commented on the company. The Goldman Sachs Group increased their price target on Solventum from $48.00 to $54.00 and gave the stock a "sell" rating in a research report on Monday, August 12th. BTIG Research started coverage on shares of Solventum in a research report on Thursday, September 5th. They set a "neutral" rating for the company. Piper Sandler lifted their price objective on shares of Solventum from $71.00 to $75.00 and gave the stock a "neutral" rating in a research note on Friday, November 8th. Wolfe Research began coverage on Solventum in a report on Thursday, September 26th. They issued a "peer perform" rating for the company. Finally, Morgan Stanley lifted their price target on Solventum from $60.00 to $73.00 and gave the company an "equal weight" rating in a research note on Monday, November 11th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has given a buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $68.00.
Read Our Latest Analysis on Solventum
About Solventum
(
Free Report)
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.
Featured Articles
Before you consider Solventum, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Solventum wasn't on the list.
While Solventum currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
